10-K: Immunome Reports 2024 Annual Results, Highlights Clinical Pipeline Progress

Immunome, a clinical-stage oncology company, provides an update on its financial results for the year ended December 31, 2024, and outlines key advancements in its targeted therapy development programs.

Summary

• Immunome, Inc. is a clinical-stage targeted oncology company focused on developing targeted therapies to improve cancer patient outcomes.
• The company is advancing a pipeline of clinical and preclinical assets, including Varegacestat, IM-1021, IM-3050, IM-1617, IM-1340, and IM-1335.
• Varegacestat is in a Phase 3 clinical trial for desmoid tumors, with topline data expected in the second half of 2025.
• IM-1021, a ROR1 antibody-drug conjugate, received IND clearance in December 2024, and a Phase 1 trial is ongoing.
• IM-3050, a FAP-targeted radioligand therapy, had an IND submitted in March 2025, with a Phase 1 clinical trial expected in the second half of 2025.
• IM-1617, IM-1340, and IM-1335 are solid tumor ADC drug candidates in IND-enabling activities.
• The company's internal discovery efforts focus on designing ADCs against novel or underexplored targets, utilizing a proprietary TOP1 inhibitor payload, HC74.
• Strategic transactions in 2024 included the acquisition of assets from Ayala Pharmaceuticals and Zentalis Pharmaceuticals.
• As of December 31, 2024, Immunome had 118 full-time employees, with 87 in research and development and 31 in general and administrative roles.
• The company reported a net loss of $293.0 million for the year ended December 31, 2024, and had an accumulated deficit of $515.8 million.
• Existing cash, cash equivalents, and marketable securities as of December 31, 2024, together with proceeds from a January 2025 financing, are expected to fund operations for at least 12 months.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While there are positive developments in the clinical pipeline and strategic transactions, the increasing net losses and reliance on future funding introduce uncertainty. The sentiment is neutral, reflecting both progress and financial challenges.

Positives

• Advancement of Varegacestat to Phase 3 clinical trial indicates progress in a key program.
• IND clearance for IM-1021 and ongoing Phase 1 trial represent a significant milestone.
• Submission of IND for IM-3050 suggests potential for expansion into radioligand therapies.
• Strategic acquisitions of assets from Ayala and Zentalis expand the company's pipeline and technology.
• Strong preclinical data for IM-1021 supports its potential as a therapeutic candidate.
• The company has a strong leadership team with experience in developing and commercializing cancer therapies.
• The company has a clear ADC development strategy focused on novel targets and unmet needs.
• The company has a proprietary TOP1 inhibitor payload, HC74, which may improve the therapeutic index of ADCs.
• The company has a robust intellectual property portfolio with 141 issued or granted patents and 117 pending applications.

Negatives

• The company has a history of losses and expects to continue incurring significant losses for the foreseeable future.
• The company has not yet demonstrated successful completion of clinical development, NDA submission, or commercialization of a product.
• Clinical trials are expensive, time-consuming, and difficult to design and implement.
• The company faces substantial competition, which may result in others discovering, developing, or commercializing products more quickly or marketing them more successfully.
• The market price of the company's common stock is expected to be volatile, and purchasers of the common stock could incur substantial losses.
• The company is subject to stringent and evolving U.S. and foreign laws, regulations, and rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security.

Risks

• The company may be unable to advance any of its product candidates into and through clinical development, obtain regulatory approvals, and ultimately commercialize them.
• The company may fail to realize the business benefits anticipated as a result of completed or future strategic transactions.
• As a targeted radioligand therapy, the company's IM-3050 program may face additional and potentially unpredictable challenges.
• If the company encounters difficulties enrolling participants in its clinical trials, its clinical development activities could be delayed or otherwise adversely affected.
• If the company or others identify undesirable side effects caused by a product candidate undergoing clinical trials, the ability to market and derive revenue from the product candidate could be compromised.
• If third parties on which the company relies to conduct its current and future preclinical and clinical studies do not perform as contractually required, fail to satisfy regulatory or legal requirements, or miss expected deadlines, the company's programs could be delayed.
• Because the company relies on third parties for manufacturing, supply, and testing, some of which may be sole source vendors, for preclinical and clinical development materials and commercial supplies, the company's supply may become limited or interrupted or may not be of satisfactory quantity or quality.
• Any inability to attract and retain qualified key management, technical personnel, and employees would impair the company's ability to implement its business plan.
• Unfavorable global economic and political conditions could adversely affect the company's business, financial condition, or results of operations.

Future Outlook

The company expects its existing cash, cash equivalents and marketable securities as of December 31, 2024, together with the proceeds of its January 2025 financing, will be sufficient to fund its current and planned operating expenses and capital expenditures for at least 12 months from the filing date of this Annual Report on Form 10-K.

Management Comments

• The document does not contain direct quotes from management.
• The document does contain paraphrased statements from management regarding the company's strategy and goals.

Industry Context

The announcement highlights Immunome's position within the competitive oncology market, specifically in targeted therapies like ADCs and radioligand therapies. It acknowledges competition from major pharmaceutical companies and other specialized oncology firms. The company emphasizes its focus on novel targets and differentiated approaches to address unmet needs in cancer treatment.

Comparison to Industry Standards

• The document mentions several competitors and their respective programs, including SpringWorks Therapeutics' OGSIVEO for desmoid tumors, Merck's zilovertamab vedotin for B-cell lymphoma, and Novartis' FAP-targeted radioligand therapy (177Lu-FAP-2286).
• The document compares IM-1021's preclinical activity to zilovertamab vedotin, suggesting a potential for improved therapeutic index.
• The document notes that a third-party randomized controlled clinical trial found that a HER2-targeted ADC with a TOP1 inhibitor payload, Enhertu, showed a significant progression-free survival benefit compared with a HER2-targeted ADC with an emtansine payload.

Stakeholder Impact

• Shareholders: Dilution from equity offerings, potential for long-term growth.
• Employees: Job security dependent on company performance and funding.
• Patients: Potential for new cancer therapies.
• Partners: Opportunities for collaboration and revenue sharing.
• Creditors: Risk associated with company's ability to repay debt.

Next Steps

• Report topline data for RINGSIDE Part B in the second half of 2025.
• Initiate a Phase 1 clinical trial for IM-3050 in the second half of 2025.
• Continue IND-enabling studies for IM-1617, IM-1340, and IM-1335.
• Continue lead optimization for six additional ADC candidates.
• Evaluate the need and benefit of developing potential companion diagnostic(s) for IM-1021.

Key Dates

Keywords

Oncology, Targeted therapy, Antibody-drug conjugate, ADC, Radioligand therapy, Clinical trial, Varegacestat, IM-1021, IM-3050, Pharmaceuticals, Biotechnology